Why the study?
Does bosentan reduce systolic blood pressure in DOCA-salt spontaneously hypertensive rats?
Population
13-week-old spontaneously hypertensive rats implanted with silastic containing DOCA and offered 1% saline to…
Comparison
Bosentan vs Untreated DOCA-salt SHR
Design
Preclinical
Authors
Loading...
Supports endothelin-1 role in malignant hypertension models; hypothesis-generating with no clinical implications yet.
Does bosentan reduce systolic blood pressure in DOCA-salt spontaneously hypertensive rats?
Bosentan significantly blunts the rise in systolic blood pressure in DOCA-salt spontaneously hypertensive rats, supporting the role of endothelin-1 in this malignant hypertension model.
Schiffrin et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: